Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191–8. https://doi.org/10.1038/ni1009.
Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281–95. https://doi.org/10.1016/j.immuni.2007.07.010.
Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225–34. https://doi.org/10.1038/ni889.
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7. https://doi.org/10.1038/nm.2446.
Johnnidis JB, Muroyama Y, Ngiow SF, Chen Z, Manne S, Cai Z, et al. Inhibitory signaling sustains a distinct early memory CD8(+) T cell precursor that is resistant to DNA damage. Sci Immunol. 2021;6. https://doi.org/10.1126/sciimmunol.abe3702
Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808–13. https://doi.org/10.1038/nm.1982.
Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med. 2005;11:1299–305. https://doi.org/10.1038/nm1326.
Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10:524–30. https://doi.org/10.1038/ni.1718.
Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med. 2010;207:553–64. https://doi.org/10.1084/jem.20090858.
Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci USA. 2010;107:17872–9. https://doi.org/10.1073/pnas.1010201107.
Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med. 2010;16:224–7. https://doi.org/10.1038/nm.2078.
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–99. https://doi.org/10.1038/nri3862.
Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205–13. https://doi.org/10.1084/jem.188.12.2205.
Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993;362:758–61. https://doi.org/10.1038/362758a0.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–4. https://doi.org/10.1038/nature05115.
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215–25. https://doi.org/10.1128/JVI.02844-06.
Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006;80:11398–403. https://doi.org/10.1128/JVI.01177-06.
Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–202. https://doi.org/10.1038/nm1482.
McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95. https://doi.org/10.1146/annurev-immunol-041015-055318.
Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and adaptive immune regulation during chronic viral infections. Annu Rev Virol. 2015;2:573–97. https://doi.org/10.1146/annurev-virology-100114-055226.
Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301–18. https://doi.org/10.1146/annurev-med-012017-043208.
Launonen IM, Niemiec I, Hincapié-Otero M, Erkan EP, Junquera A, Afenteva D, et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell. 2024;42:2045–63.e10. https://doi.org/10.1016/j.ccell.2024.11.005.
Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160–5. https://doi.org/10.1126/science.aaf2807.
Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165–9. https://doi.org/10.1126/science.aae0491.
Abdel-Hakeem MS, Manne S, Beltra JC, Stelekati E, Chen Z, Nzingha K, et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat Immunol. 2021;22:1008–19. https://doi.org/10.1038/s41590-021-00975-5.
Yates KB, Tonnerre P, Martin GE, Gerdemann U, Al Abosy R, Comstock DE, et al. Epigenetic scars of CD8(+) T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol. 2021;22:1020–9. https://doi.org/10.1038/s41590-021-00979-1.
McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612–6. https://doi.org/10.1038/nature14468.
McKinney EF, Smith KG. T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunol Cell Biol. 2016;94:935–42. https://doi.org/10.1038/icb.2016.81.
Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208:395–407. https://doi.org/10.1084/jem.20100466.
McKinney EF, Smith KG. T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. Curr Opin Immunol. 2016;43:74–80. https://doi.org/10.1016/j.coi.2016.09.005.
Zou D, Dai Y, Zhang X, Wang G, Xiao X, Jia P, et al. T cell exhaustion is associated with antigen abundance and promotes transplant acceptance. Am J Transplant. 2020;20:2540–50. https://doi.org/10.1111/ajt.15870.
Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008;117:660–9. https://doi.org/10.1161/CIRCULATIONAHA.107.741025.
Alzahrani N, Al Jurdi A, Riella LV. Immune checkpoint inhibitors in kidney transplantation. Curr Opin Organ Transplant. 2023;28:46–54. https://doi.org/10.1097/MOT.0000000000001036.
Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105:15016–21. https://doi.org/10.1073/pnas.0801497105.
Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338:1220–5. https://doi.org/10.1126/science.1229620.
Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11:e1005177. https://doi.org/10.1371/journal.ppat.1005177.
Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1. https://doi.org/10.1126/sciimmunol.aai8593
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417–21. https://doi.org/10.1038/nature19330.
He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5-expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537:412–28. https://doi.org/10.1038/nature19317.
Leong YA, Chen Y, Ong HS, Wu D, Man K, Deleage C, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17:1187–96. https://doi.org/10.1038/ni.3543.
Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45:415–27. https://doi.org/10.1016/j.immuni.2016.07.021.
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326–36. https://doi.org/10.1038/s41590-019-0312-6.
Ferrando-Martinez S, Moysi E, Pegu A, Andrews S, Nganou Makamdop K, Ambrozak D, et al. Accumulation of follicular CD8+ T cells in pathogenic SIV infection. J Clin Investig. 2018;128:2089–103. https://doi.org/10.1172/JCI96207.
Yao C, Sun HW, Lacey NE, Ji Y, Moseman EA, Shih HY, et al. Single-cell RNA-seq reveals TOX as a key regulator of CD8(+) T cell persistence in chronic infection. Nat Immunol. 2019;20:890–901. https://doi.org/10.1038/s41590-019-0403-4.
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195–211.e10. https://doi.org/10.1016/j.immuni.2018.12.021.
Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells. Immunity. 2019;50:181–94.e6. https://doi.org/10.1016/j.immuni.2018.11.014.
Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC, et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity. 2019;51:840–55 e845. https://doi.org/10.1016/j.immuni.2019.09.013.
Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan SL, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338–53.e6. https://doi.org/10.1016/j.immuni.2021.08.026.
Meiser P, Knolle MA, Hirschberger A, de Almeida GP, Bayerl F, Lacher S, et al. A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity. Cancer Cell. 2023;41:1498–515.e10. https://doi.org/10.1016/j.ccell.2023.06.008.
Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I, et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021;6:eabg7836. https://doi.org/10.1126/sciimmunol.abg7836.
Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049–66.e25. https://doi.org/10.1016/j.cell.2022.09.020.
Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465–70. https://doi.org/10.1038/s41586-019-1836-5.
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38:685–700.e8. https://doi.org/10.1016/j.ccell.2020.09.001.
Rahim MK, Okholm T, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186:1127–1143.e18. https://doi.org/10.1016/j.cell.2023.02.021.
Lan X, Mi T, Alli S, Guy C, Djekidel MN, Liu X, et al. Antitumor progenitor exhausted CD8(+) T cells are sustained by TCR engagement. Nat Immunol. 2024;25:1046–58. https://doi.org/10.1038/s41590-024-01843-8.
Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128:519–28. https://doi.org/10.1182/blood-2015-11-683847.
Zheng W, Wei J, Zebley CC, Jones LL, Dhungana Y, Wang YD, et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138:122–35. https://doi.org/10.1182/blood.2020009309.
van Bruggen J, Martens A, Fraietta JA, Hofland T, Tonino SH, Eldering E, et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy. Blood. 2019;134:44–58. https://doi.org/10.1182/blood.2018885863.
Gabriel SS, Tsui C, Chisanga D, Weber F, Llano-León M, Gubser PM, et al. Transforming growth factor-beta-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. Immunity. 2021;54:1698–714 e5. https://doi.org/10.1016/j.immuni.2021.06.007.
Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Knöpper K, et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1alpha-mediated glycolytic reprogramming. Nat Commun. 2023;14:6858. https://doi.org/10.1038/s41467-023-42634-3.
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998–1013.e20. https://doi.org/10.1016/j.cell.2018.10.038.
Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188:3081–96.e19. https://doi.org/10.1016/j.cell.2025.03.018.
Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell Therapy. Cancer Discov. 2021;11:2186–99. https://doi.org/10.1158/2159-8290.CD-20-1677.
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71. https://doi.org/10.1038/s41591-018-0010-1.
Deng Q, Han G, Puebla-Osorio N, Ma M, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26:1878–87. https://doi.org/10.1038/s41591-020-1061-7.
Gearty SV, Dündar F, Zumbo P, Espinosa-Carrasco G, Shakiba M, Sanchez-Rivera FJ, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature. 2022;602:156–61. https://doi.org/10.1038/s41586-021-04248-x.
Abdelsamed HA, Zebley CC, Nguyen H, Rutishauser RL, Fan Y, Ghoneim HE, et al. Beta cell-specific CD8(+) T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. Nat Immunol. 2020;21:578–87. https://doi.org/10.1038/s41590-020-0633-5.
Shin B, Kress RL, Kramer PA, Darley-Usmar VM, Bellis SL, Harrington LE. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation. J Exp Med. 2018;215:1803–12. https://doi.org/10.1084/jem.20172335.
Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Investig. 2006;116:1675–85. https://doi.org/10.1172/JCI26856.
Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571:265–9. https://doi.org/10.1038/s41586-019-1326-9.
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571:211–8. https://doi.org/10.1038/s41586-019-1325-x.
Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571:270–4. https://doi.org/10.1038/s41586-019-1324-y.
Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion. Proc Natl Acad Sci USA. 2019;116:12410–5. https://doi.org/10.1073/pnas.1905675116.
Wang X, He Q, Shen H, Xia A, Tian W, Yu W, et al. TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol. 2019;71:731–41. https://doi.org/10.1016/j.jhep.2019.05.015.
McManus DT, Valanparambil RM, Medina CB, Scharer CD, McGuire DJ, Sobierajska E, et al. An early precursor CD8(+) T cell that adapts to acute or chronic viral infection. Nature. 2025;640:772–81. https://doi.org/10.1038/s41586-024-08562-y.
Chu T, Wu M, Hoellbacher B, de Almeida GP, Wurmser C, Berner J, et al. Precursors of exhausted T cells are pre-emptively formed in acute infection. Nature. 2025;640:782–92. https://doi.org/10.1038/s41586-024-08451-4.
Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825–41.e8. https://doi.org/10.1016/j.immuni.2020.04.014.
Zhu Z, Lou G, Teng XL, Wang H, Luo Y, Shi W, et al. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat Immunol. 2024;25:117–28. https://doi.org/10.1038/s41590-023-01685-w.
Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609:354–60. https://doi.org/10.1038/s41586-022-05105-1.
Galletti G, De Simone G, Mazza E, Puccio S, Mezzanotte C, Bi TM, et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat Immunol. 2020;21:1552–62. https://doi.org/10.1038/s41590-020-0791-5.
Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM, Li P, et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection. Immunity. 2019;51:1043–58.e4. https://doi.org/10.1016/j.immuni.2019.11.002.
Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity. 2019;51:1028–42.e4. https://doi.org/10.1016/j.immuni.2019.10.009.
Sandu I, Cerletti D, Oetiker N, Borsa M, Wagen F, Spadafora I, et al. Landscape of exhausted virus-specific CD8 T cells in chronic LCMV infection. Cell Rep. 2020;32:108078. https://doi.org/10.1016/j.celrep.2020.108078.
Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.97828
Daniel B, Yost KE, Hsiung S, Sandor K, Xia Y, Qi Y, et al. Divergent clonal differentiation trajectories of T cell exhaustion. Nat Immunol. 2022;23:1614–27. https://doi.org/10.1038/s41590-022-01337-5.
Giles JR, Ngiow SF, Manne S, Baxter AE, Khan O, Wang P, et al. Shared and distinct biological circuits in effector, memory and exhausted CD8(+) T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat Immunol. 2022;23:1600–13. https://doi.org/10.1038/s41590-022-01338-4.
Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184:4512–30.e22. https://doi.org/10.1016/j.cell.2021.07.015.
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, et al. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell. 2024;187:4336–54.e19. https://doi.org/10.1016/j.cell.2024.07.018.
Broomfield BJ, Tan CW, Qin RZ, Abberger H, Duckworth BC, Alvarado C, et al. Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection. J Exp Med. 2025;222. https://doi.org/10.1084/jem.20241148
Chen J, López-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530–4. https://doi.org/10.1038/s41586-019-0985-x.
Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature. 2019;567:525–9. https://doi.org/10.1038/s41586-019-0979-8.
Hao J, Li R, Zhao X, Liu X, Chen X, Xie T, et al. NR4A1 transcriptionally regulates the differentiation of stem-like CD8(+) T cells in the tumor microenvironment. Cell Rep. 2024;43:114301. https://doi.org/10.1016/j.celrep.2024.114301.
Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity. 2015;42:265–78. https://doi.org/10.1016/j.immuni.2015.01.006.
Tillé L, Cropp D, Charmoy M, Reichenbach P, Andreatta M, Wyss T, et al. Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8(+) T cell exhaustion. Nat Immunol. 2023;24:1645–53. https://doi.org/10.1038/s41590-023-01614-x.
Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, et al. NFATc1 controls the cytotoxicity of CD8(+) T cells. Nat Commun. 2017;8:511. https://doi.org/10.1038/s41467-017-00612-6.
Agnellini P, Wolint P, Rehr M, Cahenzli J, Karrer U, Oxenius A. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc Natl Acad Sci USA. 2007;104:4565–70. https://doi.org/10.1073/pnas.0610335104.
Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, et al. Transcription factor IRF4 promotes CD8(+) T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity. 2017;47:1129–41.e5. https://doi.org/10.1016/j.immuni.2017.11.021.
Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010;16:1147–51. https://doi.org/10.1038/nm.2232.
Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576:471–6. https://doi.org/10.1038/s41586-019-1821-z.
Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CJ, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021;22:983–95. https://doi.org/10.1038/s41590-021-00964-8.
Escobar G, Mangani D, Anderson AC. T cell factor 1: a master regulator of the T cell response in disease. Sci Immunol. 2020;5. https://doi.org/10.1126/sciimmunol.abb9726
Weber BN, Chi AW, Chavez A, Yashiro-Ohtani Y, Yang Q, Shestova O, et al. A critical role for TCF-1 in T-lineage specification and differentiation. Nature. 2011;476:63–8. https://doi.org/10.1038/nature10279.
Germar K, Dose M, Konstantinou T, Zhang J, Wang H, Lobry C, et al. T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proc Natl Acad Sci USA. 2011;108:20060–5. https://doi.org/10.1073/pnas.1110230108.
Johnson JL, Georgakilas G, Petrovic J, Kurachi M, Cai S, Harly C, et al. Lineage-determining transcription factor TCF-1 initiates the epigenetic identity of T cells. Immunity. 2018;48:243–57.e10. https://doi.org/10.1016/j.immuni.2018.01.012.
Xing S, Li F, Zeng Z, Zhao Y, Yu S, Shan Q, et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat Immunol. 2016;17:695–703. https://doi.org/10.1038/ni.3456.
Shan Q, Zhu S, Chen X, Liu J, Yuan S, Li X, et al. Tcf1-CTCF cooperativity shapes genomic architecture to promote CD8(+) T cell homeostasis. Nat Immunol. 2022;23:1222–35. https://doi.org/10.1038/s41590-022-01263-6.
Jeannet G, Boudousquié C, Gardiol N, Kang J, Huelsken J, Held W. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc Natl Acad Sci USA. 2010;107:9777–82. https://doi.org/10.1073/pnas.0914127107.
Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity. 2010;33:229–40. https://doi.org/10.1016/j.immuni.2010.08.002.
Pais Ferreira D, Silva JG, Wyss T, Fuertes Marraco SA, Scarpellino L, Charmoy M, et al. Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effector cells in the absence of cytotoxic differentiation. Immunity. 2020;53:985–1000.e11. https://doi.org/10.1016/j.immuni.2020.09.005.
Gullicksrud JA, Li F, Xing S, Zeng Z, Peng W, Badovinac VP, et al. Differential Requirements for Tcf1 Long Isoforms in CD8(+) and CD4(+) T Cell Responses to Acute Viral Infection. J Immunol. 2017;199:911–9. https://doi.org/10.4049/jimmunol.1700595.
Wu T, Shin HM, Moseman EA, Ji Y, Huang B, Harly C, et al. TCF1 is required for the T follicular helper cell response to viral infection. Cell Rep. 2015;12:2099–110. https://doi.org/10.1016/j.celrep.2015.08.049.
Huang Z, Zak J, Pratumchai I, Shaabani N, Vartabedian VF, Nguyen N, et al. IL-27 promotes the expansion of self-renewing CD8(+) T cells in persistent viral infection. J Exp Med. 2019;216:1791–808. https://doi.org/10.1084/jem.20190173.
Beltra JC, Abdel-Hakeem MS, Manne S, Zhang Z, Huang H, Kurachi M, et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure. Immunity. 2023;56:2699–718.e11. https://doi.org/10.1016/j.immuni.2023.11.005.
Tsukumo S, Unno M, Muto A, Takeuchi A, Kometani K, Kurosaki T, et al. Bach2 maintains T cells in a naive state by suppressing effector memory-related genes. Proc Natl Acad Sci USA. 2013;110:10735–40. https://doi.org/10.1073/pnas.1306691110.
Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature. 2013;498:506–10. https://doi.org/10.1038/nature12199.
Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, et al. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol. 2016;17:851–60. https://doi.org/10.1038/ni.3441.
Grant FM, Yang J, Nasrallah R, Clarke J, Sadiyah F, Whiteside SK, et al. BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression. J Exp Med. 2020;217. https://doi.org/10.1084/jem.20190711
Sidwell T, Liao Y, Garnham AL, Vasanthakumar A, Gloury R, Blume J, et al. Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell differentiation and homeostasis. Nat Commun. 2020;11:252. https://doi.org/10.1038/s41467-019-14112-2.
Yao C, Lou G, Sun HW, Zhu Z, Sun Y, Chen Z, et al. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8(+) T cells. Nat Immunol. 2021;22:370–80. https://doi.org/10.1038/s41590-021-00868-7.
Utzschneider DT, Gabriel SS, Chisanga D, Gloury R, Gubser PM, Vasanthakumar A, et al. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat Immunol. 2020;21:1256–66. https://doi.org/10.1038/s41590-020-0760-z.
Hu T, Zhu Z, Luo Y, Wizzard S, Hoar J, Shinde SS, et al. BACH2 dosage establishes the hierarchy of stemness and finetunes antitumor immunity in CAR T cells. bioRxiv [Preprint]. 2025. https://doi.org/10.1101/2025.08.18.670909
Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8:153–66. https://doi.org/10.1016/j.devcel.2004.12.015.
Soza-Ried C, Hess I, Netuschil N, Schorpp M, Boehm T. Essential role of c-myb in definitive hematopoiesis is evolutionarily conserved. Proc Natl Acad Sci USA. 2010;107:17304–8. https://doi.org/10.1073/pnas.1004640107.
Bender TP, Kremer CS, Kraus M, Buch T, Rajewsky K. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol. 2004;5:721–9. https://doi.org/10.1038/ni1085.
Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP. Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci USA. 2004;101:14853–8. https://doi.org/10.1073/pnas.0405338101.
Badiani P, Corbella P, Kioussis D, Marvel J, Weston K. Dominant interfering alleles define a role for c-Myb in T-cell development. Genes Dev. 1994;8:770–82. https://doi.org/10.1101/gad.8.7.770.
Chen Z, Stelekati E, Kurachi M, Yu S, Cai Z, Manne S, et al. miR-150 regulates memory CD8 T cell differentiation via c-Myb. Cell Rep. 2017;20:2584–97. https://doi.org/10.1016/j.celrep.2017.08.060.
Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, et al. The transcription factor c-Myb regulates CD8(+) T cell stemness and antitumor immunity. Nat Immunol. 2019;20:337–49. https://doi.org/10.1038/s41590-018-0311-z.
Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423:550–5. https://doi.org/10.1038/nature01667.
Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, DePinho RA, et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol. 2009;10:176–84. https://doi.org/10.1038/ni.1689.
Kim MV, Ouyang W, Liao W, Zhang MQ, Li MO. The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Immunity. 2013;39:286–97. https://doi.org/10.1016/j.immuni.2013.07.013.
Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity. 2012;36:374–87. https://doi.org/10.1016/j.immuni.2012.01.015.
Hess Michelini R, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med. 2013;210:1189–200. https://doi.org/10.1084/jem.20130392.
Delpoux A, Lai CY, Hedrick SM, Doedens AL. FOXO1 opposition of CD8(+) T cell effector programming confers early memory properties and phenotypic diversity. Proc Natl Acad Sci USA. 2017;114:E8865–74. https://doi.org/10.1073/pnas.1618916114.
Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41:802–14. https://doi.org/10.1016/j.immuni.2014.10.013.
Utzschneider DT, Delpoux A, Wieland D, Huang X, Lai CY, Hofmann M, et al. Active maintenance of T cell memory in acute and chronic viral infection depends on continuous expression of FOXO1. Cell Rep. 2018;22:3454–67. https://doi.org/10.1016/j.celrep.2018.03.020.
Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45:358–73. https://doi.org/10.1016/j.immuni.2016.07.008.
Feng X, Wang H, Takata H, Day TJ, Willen J, Hu H. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol. 2011;12:544–50. https://doi.org/10.1038/ni.2034.
Konopacki C, Pritykin Y, Rubtsov Y, Leslie CS, Rudensky AY. Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function. Nat Immunol. 2019;20:232–42. https://doi.org/10.1038/s41590-018-0291-z.
Ren J, Han L, Tang J, Liu Y, Deng X, Liu Q, et al. Foxp1 is critical for the maintenance of regulatory T-cell homeostasis and suppressive function. PLoS Biol. 2019;17:e3000270. https://doi.org/10.1371/journal.pbio.3000270.
Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, et al. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity. 2014;41:427–39. https://doi.org/10.1016/j.immuni.2014.08.012.
Carlson CM, Endrizzi BT, Wu J, Ding X, Weinreich MA, Walsh ER, et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature. 2006;442:299–302. https://doi.org/10.1038/nature04882.
Weinreich MA, Takada K, Skon C, Reiner SL, Jameson SC, Hogquist KA. KLF2 transcription-factor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors. Immunity. 2009;31:122–30. https://doi.org/10.1016/j.immuni.2009.05.011.
Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol. 2013;14:1285–93. https://doi.org/10.1038/ni.2745.
Zhu Z, Lou G, Luo Y, Yihunie K, Hoar J, Daniel JA, et al. Aging compromises terminal differentiation program of cytotoxic effector lineage and promotes exhaustion in CD8(+) T cells responding to coronavirus infection. Aging Cell. 2025;24:e70109. https://doi.org/10.1111/acel.70109.
Fagerberg E, Attanasio J, Dien C, Singh J, Kessler EA, Abdullah L, et al. KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection. Science. 2025;387:eadn2337. https://doi.org/10.1126/science.adn2337.
Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629:211–8. https://doi.org/10.1038/s41586-024-07300-8.
Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372. https://doi.org/10.1126/science.aba1786
Durand A, Bonilla N, Level T, Ginestet Z, Lombès A, Guichard V, et al. Type 1 interferons and Foxo1 down-regulation play a key role in age-related T-cell exhaustion in mice. Nat Commun. 2024;15:1718. https://doi.org/10.1038/s41467-024-45984-8.
Ban YH, Oh SC, Seo SH, Kim SM, Choi IP, Greenberg PD, et al. miR-150-mediated Foxo1 regulation programs CD8(+) T cell differentiation. Cell Rep. 2017;20:2598–611. https://doi.org/10.1016/j.celrep.2017.08.065.
Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005;6:1236–44. https://doi.org/10.1038/ni1268.
Yang CY, Best JA, Knell J, Yang E, Sheridan AD, Jesionek AK, et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol. 2011;12:1221–9. https://doi.org/10.1038/ni.2158.
Milner JJ, Toma C, He Z, Kurd NS, Nguyen QP, McDonald B, et al. Heterogenous populations of tissue-resident CD8(+) T cells are generated in response to infection and malignancy. Immunity. 2020;52:808–24.e7. https://doi.org/10.1016/j.immuni.2020.04.007.
Sun Q, Cai D, Liu D, Zhao X, Li R, Xu W, et al. BCL6 promotes a stem-like CD8(+) T cell program in cancer via antagonizing BLIMP1. Sci Immunol. 2023;8:eadh1306. https://doi.org/10.1126/sciimmunol.adh1306.
Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol. 2010;11:114–20. https://doi.org/10.1038/ni.1837.
Sun Q, Zhao X, Li R, Liu D, Pan B, Xie B, et al. STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection. J Exp Med. 2023;220. https://doi.org/10.1084/jem.20220686
Gil MP, Ploquin MJ, Watford WT, Lee SH, Kim K, Wang X, et al. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood. 2012;120:3718–28. https://doi.org/10.1182/blood-2012-05-428672.
Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12:749–61. https://doi.org/10.1038/nri3307.
Guan T, Dominguez CX, Amezquita RA, Laidlaw BJ, Cheng J, Henao-Mejia J, et al. ZEB1, ZEB2, and the miR-200 family form a counterregulatory network to regulate CD8(+) T cell fates. J Exp Med. 2018;215:1153–68. https://doi.org/10.1084/jem.20171352.
Omilusik KD, Best JA, Yu B, Goossens S, Weidemann A, Nguyen JV, et al. Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. J Exp Med. 2015;212:2027–39. https://doi.org/10.1084/jem.20150194.
Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science. 2003;302:1041–3. https://doi.org/10.1126/science.1090148.
Li J, He Y, Hao J, Ni L, Dong C. High levels of eomes promote exhaustion of anti-tumor CD8(+) T cells. Front Immunol. 2018;9:2981. https://doi.org/10.3389/fimmu.2018.02981.
Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 2014;10:e1004251. https://doi.org/10.1371/journal.ppat.1004251.
Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, Ahmed R, et al. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med. 2014;211:515–27. https://doi.org/10.1084/jem.20130208.
Xin A, Masson F, Liao Y, Preston S, Guan T, Gloury R, et al. A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet. Nat Immunol. 2016;17:422–32. https://doi.org/10.1038/ni.3410.
Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity. 2009;31:283–95. https://doi.org/10.1016/j.immuni.2009.06.021.
Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, Meffre E, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31:296–308. https://doi.org/10.1016/j.immuni.2009.05.014.
McLane LM, Ngiow SF, Chen Z, Attanasio J, Manne S, Ruthel G, et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 2021;35:109120. https://doi.org/10.1016/j.celrep.2021.109120.
Ran L, Yue Z, Ran M, Liu Q, Su X, Wang L, et al. The transcription regulator ID3 maintains tumor-specific memory CD8(+) T cells in draining lymph nodes during tumorigenesis. Cell Rep. 2024;43:114690. https://doi.org/10.1016/j.celrep.2024.114690.
Gago da Graça C, Sheikh AA, Newman DM, Wen L, Li S, Shen J, et al. Stem-like memory and precursors of exhausted T cells share a common progenitor defined by ID3 expression. Sci Immunol. 2025;10:eadn1945. https://doi.org/10.1126/sciimmunol.adn1945.
Lin S, Niu H, Zhang Y, Gai K, Brown R, Brown A, et al. SATB1 is a key regulator of quiescence in stem-like CD8(+) T cells. Nat Immunol. 2025;26:1737–51. https://doi.org/10.1038/s41590-025-02257-w.
Heyden L, Rausch L, Shannon MH, Dryburgh L, Moreira ML, Frolov A, et al. Transcriptional regulator SATB1 limits CD8(+) T cell population expansion and effector differentiation in chronic infection and cancer. Nat Immunol. 2025;26:2312–27. https://doi.org/10.1038/s41590-025-02316-2.
Chen Z, Arai E, Khan O, Zhang Z, Ngiow SF, He Y, et al. In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021;184:1262–80.e22. https://doi.org/10.1016/j.cell.2021.02.019.
Shan Q, Zeng Z, Xing S, Li F, Hartwig SM, Gullicksrud JA, et al. The transcription factor Runx3 guards cytotoxic CD8(+) effector T cells against deviation towards follicular helper T cell lineage. Nat Immunol. 2017;18:931–9. https://doi.org/10.1038/ni.3773.
Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med. 2009;206:51–9. https://doi.org/10.1084/jem.20081242.
Wang D, Diao H, Getzler AJ, Rogal W, Frederick MA, Milner J, et al. The transcription factor Runx3 establishes chromatin accessibility of cis-regulatory landscapes that drive memory cytotoxic T lymphocyte formation. Immunity. 2018;48:659–74.e6. https://doi.org/10.1016/j.immuni.2018.03.028.
Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, et al. Erratum: Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature. 2018;554:392. https://doi.org/10.1038/nature25445.
Wu JE, Manne S, Ngiow SF, Baxter AE, Huang H, Freilich E, et al. In vitro modeling of CD8(+) T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40. Sci Immunol. 2023;8:eade3369. https://doi.org/10.1126/sciimmunol.ade3369.
Chen Z, Javed N, Moore M, Wu J, Sun G, Vinyard M, et al. Integrative dissection of gene regulatory elements at base resolution. Cell Genom. 2023;3:100318. https://doi.org/10.1016/j.xgen.2023.100318.
Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell. 2017;171:1221–3. https://doi.org/10.1016/j.cell.2017.11.006.
Wagle MV, Vervoort SJ, Kelly MJ, Van Der Byl W, Peters TJ, Martin BP, et al. Antigen-driven EGR2 expression is required for exhausted CD8(+) T cell stability and maintenance. Nat Commun. 2021;12:2782. https://doi.org/10.1038/s41467-021-23044-9.
Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45:374–88. https://doi.org/10.1016/j.immuni.2016.07.009.
Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 2016;16:1243–52. https://doi.org/10.1016/j.celrep.2016.06.078.
Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017;23:327–36. https://doi.org/10.1038/nm.4275.
Sugiura A, Rathmell JC. Metabolic barriers to T cell function in tumors. J Immunol. 2018;200:400–7. https://doi.org/10.4049/jimmunol.1701041.
Yu YR, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion. Nat Immunol. 2020;21:1540–51. https://doi.org/10.1038/s41590-020-0793-3.
Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217–28. https://doi.org/10.1016/j.cell.2015.08.012.
Sinclair LV, Howden AJ, Brenes A, Spinelli L, Hukelmann JL, Macintyre AN, et al. Antigen receptor control of methionine metabolism in T cells. eLife. 2019;8. https://doi.org/10.7554/eLife.44210
Peng M, Yin N, Chhangawala S, Xu K, Leslie CS, Li MO. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science. 2016;354:481–4. https://doi.org/10.1126/science.aaf6284.
Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324:1076–80. https://doi.org/10.1126/science.1164097.
Ma S, Dahabieh MS, Mann TH, Zhao S, McDonald B, Song WS, et al. Nutrient-driven histone code determines exhausted CD8(+) T cell fates. Science. 2025;387:eadj3020. https://doi.org/10.1126/science.adj3020.
Kaymak I, Watson MJ, Oswald BM, Ma S, Johnson BK, DeCamp LM, et al. ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses. J Exp Med. 2024;221. https://doi.org/10.1084/jem.20231820
Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–42. https://doi.org/10.1016/j.immuni.2005.03.013.
Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1:1460–8. https://doi.org/10.4161/onci.21716.
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203. https://doi.org/10.1038/nature10491.
Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553–60. https://doi.org/10.1158/0008-5472.CAN-08-1921.
Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, et al. Serine is an essential metabolite for effector T cell expansion. Cell Metab. 2017;25:345–57. https://doi.org/10.1016/j.cmet.2016.12.011.
Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab. 2019;30:143–56.e5. https://doi.org/10.1016/j.cmet.2019.04.002.
Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity. 2021;54:1561–77.e7. https://doi.org/10.1016/j.immuni.2021.05.003.
Yan C, Zheng L, Jiang S, Yang H, Guo J, Jiang LY, et al. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. Cancer Cell. 2023;41:1276–93.e11. https://doi.org/10.1016/j.ccell.2023.04.016.
Varanasi SK, Chen D, Liu Y, Johnson MA, Miller CM, Ganguly S, et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science. 2025;387:192–201. https://doi.org/10.1126/science.adl4100.
Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol. 2013;14:1173–82. https://doi.org/10.1038/ni.2714.
Palazon A, Tyrakis PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, et al. An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell. 2017;32:669–83.e5. https://doi.org/10.1016/j.ccell.2017.10.003.
Phan AT, Doedens AL, Palazon A, Tyrakis PA, Cheung KP, Johnson RS, et al. Constitutive glycolytic metabolism supports CD8(+) T cell effector memory differentiation during viral infection. Immunity. 2016;45:1024–37. https://doi.org/10.1016/j.immuni.2016.10.017.
Vuillefroy de Silly R, Ducimetière L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR. Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells. Eur J Immunol. 2015;45:2263–75. https://doi.org/10.1002/eji.201445284.
Scharping NE, Rivadeneira DB, Menk AV, Vignali P, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22:205–15. https://doi.org/10.1038/s41590-020-00834-9.
Vignali P, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24:267–79. https://doi.org/10.1038/s41590-022-01379-9.
Ma K, Cheng H, Wang L, Xiao H, Liu F, Yang Y, et al. Succinate preserves CD8(+) T cell fitness to augment antitumor immunity. Immunity. 2025;58:2505–23. https://doi.org/10.1016/j.immuni.2025.07.017.
Cheng H, Qiu Y, Xu Y, Chen L, Ma K, Tao M, et al. Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness. Nat Metab. 2023;5:314–30. https://doi.org/10.1038/s42255-022-00730-6.
Tang K, Zhang H, Deng J, Wang D, Liu S, Lu S, et al. Ammonia detoxification promotes CD8(+) T cell memory development by urea and citrulline cycles. Nat Immunol. 2023;24:162–73. https://doi.org/10.1038/s41590-022-01365-1.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812–9. https://doi.org/10.1182/blood-2006-07-035972.
Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016;537:539–43. https://doi.org/10.1038/nature19364.
Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science 2019;363. https://doi.org/10.1126/science.aau0135
Zhang J, Li J, Hou Y, Lin Y, Zhao H, Shi Y, et al. Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor. Cell. 2024;187:3409–26.e24. https://doi.org/10.1016/j.cell.2024.04.023.
Imboden JB, Stobo JD. Transmembrane signalling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. J Exp Med. 1985;161:446–56. https://doi.org/10.1084/jem.161.3.446.
Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21:1022–33. https://doi.org/10.1038/s41590-020-0725-2.
Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. 2013;38:225–36. https://doi.org/10.1016/j.immuni.2012.10.020.
Zhu Z, Luo Y, Lou G, Yihunie K, Wizzard S, DeVilbiss AW, et al. The redox sensor KEAP1 facilitates adaptation of T cells to chronic antigen stimulation by preventing hyperactivation. Sci Immunol. 2024;9:eadk2954. https://doi.org/10.1126/sciimmunol.adk2954.
Dahabieh MS, DeCamp LM, Oswald BM, Kitchen-Goosen SM, Fu Z, Vos M, et al. The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8(+) T cell exhaustion. Nat Immunol. 2025;26:1139–51. https://doi.org/10.1038/s41590-025-02185-9.
Gnanaprakasam J, Kushwaha B, Liu L, Chen X, Kang S, Wang T, et al. Asparagine restriction enhances CD8(+) T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response. Nat Metab. 2023;5:1423–39. https://doi.org/10.1038/s42255-023-00856-1.
Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol. 2020;20:128–36. https://doi.org/10.1038/s41577-019-0223-7.
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004. https://doi.org/10.1038/s41591-018-0057-z.
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2019;176:404. https://doi.org/10.1016/j.cell.2018.12.034.
Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578–93.e8. https://doi.org/10.1016/j.ccell.2021.09.010.
Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell. 2021;39:662–77 e666. https://doi.org/10.1016/j.ccell.2021.03.007.
Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A, et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2020;181:747 https://doi.org/10.1016/j.cell.2020.04.017.
van der Leun AM, Traets J, Vos JL, Elbers J, Patiwael S, Qiao X, et al. Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T-cell and activated treg compartment. Cancer Discov. 2023;13:2212–27. https://doi.org/10.1158/2159-8290.CD-22-0851.
Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9:2724. https://doi.org/10.1038/s41467-018-05072-0.
Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342–56.e16. https://doi.org/10.1016/j.cell.2017.05.035.
Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268–72. https://doi.org/10.1038/s41586-018-0694-x.
Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978–85. https://doi.org/10.1038/s41591-018-0045-3.
Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474. https://doi.org/10.1126/science.abe6474.
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med. 2022;14:eabn7336. https://doi.org/10.1126/scitranslmed.abn7336.
Jackson Z, Hong C, Schauner R, Dropulic B, Caimi PF, de Lima M, et al. Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discov. 2022;12:1886–903. https://doi.org/10.1158/2159-8290.CD-21-1586.
Cheng J, Xiao Y, Peng T, Zhang Z, Qin Y, Wang Y, et al. ETV7 limits the antiviral and antitumor efficacy of CD8(+) T cells by diverting their fate toward exhaustion. Nat Cancer. 2025;6:338–56. https://doi.org/10.1038/s43018-024-00892-0.
Wang D, Prager BC, Gimple RC, Aguilar B, Alizadeh D, Tang H, et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov. 2021;11:1192–211. https://doi.org/10.1158/2159-8290.CD-20-1243.
Pace L, Goudot C, Zueva E, Gueguen P, Burgdorf N, Waterfall JJ, et al. The epigenetic control of stemness in CD8(+) T cell fate commitment. Science. 2018;359:177–86. https://doi.org/10.1126/science.aah6499.
Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, et al. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function. Cancer Discov. 2024;14:142–57. https://doi.org/10.1158/2159-8290.CD-22-1319.
Kang TG, Lan X, Mi T, Chen H, Alli S, Lim SE, et al. Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science. 2024;386:eadl4492. https://doi.org/10.1126/science.adl4492.
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307–12. https://doi.org/10.1038/s41586-018-0178-z.
Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170:142–57.e19. https://doi.org/10.1016/j.cell.2017.06.007.
Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293–300. https://doi.org/10.1038/s41586-019-1805-z.
Kurachi M, Barnitz RA, Yosef N, Odorizzi PM, DiIorio MA, Lemieux ME, et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol. 2014;15:373–83. https://doi.org/10.1038/ni.2834.
Chen Y, Zander RA, Wu X, Schauder DM, Kasmani MY, Shen J, et al. BATF regulates progenitor to cytolytic effector CD8(+) T cell transition during chronic viral infection. Nat Immunol. 2021;22:996–1007. https://doi.org/10.1038/s41590-021-00965-7.
Zhang X, Zhang C, Qiao M, Cheng C, Tang N, Lu S, et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell. 2022;40:1407–22.e7. https://doi.org/10.1016/j.ccell.2022.09.013.
Wang L, Jin G, Zhou Q, Liu Y, Zhao X, Li Z, et al. Induction of immortal-like and functional CAR T cells by defined factors. J Exp Med. 2024;221. https://doi.org/10.1084/jem.20232368
Grange M, Verdeil G, Arnoux F, Griffon A, Spicuglia S, Maurizio J, et al. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-beta1 signaling. J Immunol. 2013;191:3712–24. https://doi.org/10.4049/jimmunol.1300319.
Hashimoto M, Araki K, Cardenas MA, Li P, Jadhav RR, Kissick HT, et al. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program. Nature. 2022;610:173–81. https://doi.org/10.1038/s41586-022-05257-0.
Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, et al. An engineered IL-2 partial agonist promotes CD8(+) T cell stemness. Nature. 2021;597:544–8. https://doi.org/10.1038/s41586-021-03861-0.
Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42:1693–704. https://doi.org/10.1038/s41587-023-02060-8.
Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis. Cancer Cell. 2019;35:901–15.e4. https://doi.org/10.1016/j.ccell.2019.05.005.
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454–61. https://doi.org/10.1038/s41591-019-0357-y.
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60–5. https://doi.org/10.1038/nature22079.
Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, et al. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021;11:1353–67. https://doi.org/10.1158/2159-8290.CD-20-1312.
Chen Y, Wang D, Li Y, Qi L, Si W, Bo Y, et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024;42:1268–85.e7. https://doi.org/10.1016/j.ccell.2024.06.009.
Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML, et al. Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell. 2023;41:1662–79.e7. https://doi.org/10.1016/j.ccell.2023.08.001.
Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016;167:419–432 e416. https://doi.org/10.1016/j.cell.2016.09.011.
Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13. https://doi.org/10.1126/scitranslmed.abe7378
Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino M, Tonai Y, et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021;371:1166–71. https://doi.org/10.1126/science.abc1855.
Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018;359:1037–42. https://doi.org/10.1126/science.aar3246.
Zhang Q, Hresko ME, Picton LK, Su L, Hollander MJ, Nunez-Cruz S, et al. A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med. 2021;13:eabg6986. https://doi.org/10.1126/scitranslmed.abg6986.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609:369–74. https://doi.org/10.1038/s41586-022-05140-y.
Weiss SA, Huang AY, Fung ME, Martinez D, Chen A, LaSalle TJ, et al. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. Nat Immunol. 2024;25:1871–83. https://doi.org/10.1038/s41590-024-01961-3.
Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nat Commun. 2021;12:6831. https://doi.org/10.1038/s41467-021-27179-7.
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024;221. https://doi.org/10.1084/jem.20231519
Bonazzi S, d’Hennezel E, Beckwith R, Xu L, Fazal A, Magracheva A, et al. Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem Biol. 2023;30:235–47.e12. https://doi.org/10.1016/j.chembiol.2023.02.005.
Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43:114065. https://doi.org/10.1016/j.celrep.2024.114065.
Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2016;22:4119–32. https://doi.org/10.1158/1078-0432.CCR-15-2584.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell. 2025;43:49–68.e9. https://doi.org/10.1016/j.ccell.2024.11.006.
Kagoya Y, Nakatsugawa M, Yamashita Y, Ochi T, Guo T, Anczurowski M, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016;126:3479–94. https://doi.org/10.1172/JCI86437.
Milner JJ, Toma C, Quon S, Omilusik K, Scharping NE, Dey A, et al. Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection. J Exp Med. 2021;218. https://doi.org/10.1084/jem.20202512
Fan F, Yoo HJ, Stock S, Wang L, Liu Y, Schubert ML, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148:419–28. https://doi.org/10.1002/ijc.33212.
Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2017;2. https://doi.org/10.1172/jci.insight.95103
Wang X, Tao X, Chen P, Jiang P, Li W, Chang H, et al. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Signal Transduct Target Ther. 2024;9:293. https://doi.org/10.1038/s41392-024-01986-y.
Ma J, Tang L, Tan Y, Xiao J, Wei K, Zhang X, et al. Lithium carbonate revitalizes tumor-reactive CD8(+) T cells by shunting lactic acid into mitochondria. Nat Immunol. 2024;25:552–61. https://doi.org/10.1038/s41590-023-01738-0.